Lv1
38 积分 2021-11-18 加入
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
1个月前
已完结
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis
1个月前
已完结
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma
1个月前
已完结
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
1个月前
已完结
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Head and neck cancer
2个月前
已完结
Head and neck cancer
2个月前
已完结
65MO Neoadjuvant HLX11 versus European Union (EU)-sourced pertuzumab in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative early or locally advanced, breast cancer (BC): A double-blind, randomised phase III equivalence study
2个月前
已关闭
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2个月前
已完结
皖公网安备34019202002308
